James Liao named as new candidate to helm Taiwan's Academia Sinica

Academia Sinica

Academic researcher James Liao has been named as the choice to become the new head of Taiwan's Academia Sinica, closing a chapter at the top academic research body that saw potential future Nobel Prize winner Wong Chi-huey resign last month under a cloud for a controversial sale of shares in biotech OBI Pharma by his daughter.

China Post reported that Taiwan's new president and biotech booster Tsai Ing-wen has selected Liao to take the helm as the 11th president of the respected research academy with a formal announcement due later this week. The board of the institute is expected to first confirm the appointment.

Liao is currently in the United States where he holds a top academic post at the Institute for Genomics and Proteomics of the University of California, Los Angeles.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

His area of research covers metabolic engineering, synthetic biology and systems biology. He earned a doctorate from the University of Wisconsin, according to China Post.

Wong resigned last month after issuing an apology that said he was responsible for the sale of 3 million shares in OBI Pharma just before data was published from the company's key cancer drug showed it had failed a key trial.

- here's the story from China Post

 

Read more on

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.